1. Home
  2. TBPH vs CRMD Comparison

TBPH vs CRMD Comparison

Compare TBPH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$19.87

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo CorMedix Inc.

CRMD

CorMedix Inc.

HOLD

Current Price

$8.15

Market Cap

958.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
CRMD
Founded
2013
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
958.1M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
TBPH
CRMD
Price
$19.87
$8.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$27.80
$15.29
AVG Volume (30 Days)
376.6K
4.2M
Earning Date
02-25-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.58
2.25
Revenue
$80,327,000.00
$214,303,672.00
Revenue This Year
$70.78
$629.55
Revenue Next Year
N/A
$8.34
P/E Ratio
$32.64
$3.45
Revenue Growth
27.12
1647.67
52 Week Low
$7.90
$5.60
52 Week High
$21.03
$17.43

Technical Indicators

Market Signals
Indicator
TBPH
CRMD
Relative Strength Index (RSI) 54.78 43.92
Support Level $18.78 $7.66
Resistance Level $21.03 $7.59
Average True Range (ATR) 0.81 0.38
MACD -0.15 0.16
Stochastic Oscillator 45.60 81.06

Price Performance

Historical Comparison
TBPH
CRMD

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CRMD CorMedix Inc.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Share on Social Networks: